Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225Ac-PSMA-617

Lu-177-prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer has emerged as a very promising therapy. However, some of the PSMA-expressing positive metastatic castration-resistant prostate cancer patients never respond or develop resistance to Lu-177-PSMA. We present a case of castration-resistant prostate cancer with multiple bone metastases. Remission of clinical symptoms and imaging lesions can be observed after 4 cycles of Ac-225-PSMA-617 therapy. Moreover, the man did not have any observable adverse effects.

Automated summary

This article presents a case of castration-resistant prostate cancer with multiple bone metastases, where remission of clinical symptoms and imaging lesions were observed after 4 cycles of Ac-225-PSMA-617 therapy, with no observable adverse effects.